Identification of stage biomarkers for human African trypanosomiasis

American Journal of Tropical Medicine and Hygiene

Volumn 82, Issue 6, 2010, Pages 983-990

  Amin, Daniel Ndem ^a   Ngoyi, Dieudonné Mumba ^b   Nhkwachi, Gondwe Mphepo ^c   Palomba, Maria ^d   Rottenberg, Martin ^a   Büscher, Philippe ^e   Kristensson, Krister ^a   Masocha, Willias ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Institut National de Recherche Biomedicale   (Congo)

^c Ctr for Ticks and Tick borne Dis   (Malawi)

^d UNIVERSITY OF VERONA   (Italy)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOISOVALERATE DEHYDROGENASE (LIPOAMIDE); BIGLYCAN; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARRIER PROTEIN; CERULOPLASMIN; CYSTATIN C; CYSTEINE PROTEINASE INHIBITOR; CYSTEINE RICH PROTEIN 61; EPHRIN RECEPTOR A4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; MIDKINE; NEURONAL PENTRAXIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROMININ 1; REELIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SPONDIN 1; ST6 (ALPHA N ACETYL NEURAMINYL 2 3 BETA GALACTOSYL 1,3) N ACETYLGALACTOSAMINIDE ALPHA 2 6 SIALYLTRANSFERASE 5; SURAMIN; SYNDECAN 4; UNCLASSIFIED DRUG; VIMENTIN;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; RAT; SALIVA; SERUM; TRYPANOSOMA BRUCEI; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; UPREGULATION; URINE LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; GENE EXPRESSION REGULATION; HUMANS; LIPOCALINS; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SPECIFIC PATHOGEN-FREE ORGANISMS; TRYPANOSOMIASIS, AFRICAN;

MUS; RATTUS; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 77953773514     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0770     Document Type: Article

References (35)

1. Dumas M, Preux PM, Sagui E, 2009. Neurology in developing countries. Med Trop 69: 5-6.
2. Kristensson K, Mhlanga JD, Bentivoglio M, 2002. Parasites and the brain: neuroinvasion, immunopathogenesis and neuronal dysfunctions. Curr Top Microbiol Immunol 265: 227-257. (Pubitemid 34241987)
3. Bouteille B, Oukem O, Bisser S, Dumas M, 2003. Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 17: 171-181. (Pubitemid 36513208)
4. Kennedy PG, 2004. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 113: 496-504. (Pubitemid 38542496)
5. World Health Organization (WHO), 1998. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 881: 1-114.
6. Lejon V, Büscher P, 2001. Stage determination and follow-up in sleeping sickness. Med Trop 61: 355-360. (Pubitemid 33630381)
7. Bisser S, Lejon V, Preux PM, Bouteille B, Stanghellini A, Jauberteau MO, Büscher P, Dumas M, 2002. Blood-cerebrospinal fluid barrier and intrathecal immunoglobulins compared to field diagnosis of central nervous system involvement in sleeping sickness. J Neurol Sci 193: 127-135. (Pubitemid 34098944)
8. Kennedy PG, 2008. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64: 116-126.
9. Lejon V, Roger I, Mumba Ngoyi D, Menten J, Robays J, N'siesi FX, Bisser S, Boelaert M, Büscher P, 2008. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Clin Infect Dis 47: 15-22.
10. Ngotho M, Kagira JM, Jensen HE, Karanja SM, Farah IO, Hau J, 2009. Immunospecific immunoglobulins and IL-10 as markers for Trypanosoma brucei rhodesiense late stage disease in experimentally infected vervet monkeys. Trop Med Int Health 14: 736-747.
11. Lejon V, Robays J, N'Siesi FX, Mumba D, Hoogstoel A, Bisser S, Reiber H, Boelaert M, Büscher P, 2007. Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. Clin Vaccine Immunol 14: 732-737.
12. Amin DN, Rottenberg ME, Thomsen AR, Mumba D, Fenger C, Kristensson K, Büscher P, Finsen B, Masocha W, 2009. Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. J Infectious Dis 200: 1556-1565.
13. Courtioux B, Pervieux L, Vatunga G, Marin B, Josenando T, Jauberteau-Marchan MO, Bouteille B, Bisser S, 2009. Increased CXCL-13 levels in human African trypanosomiasis meningoencephalitis. Trop Med Int Health 14: 529-534.
14. Hainard A, Tiberti N, Robin X, Lejon V, Ngoyi DM, Matovu E, Enyaru JC, Fouda C, Ndung'u JM, Lisacek F, Müller M, Turck N, Sanchez JC, 2009. A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis 16: e459.
15. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, Mertens J, Mulunda J-P, Van Nieuwenhove S, Muyembe Tamfum J-J, Büscher P, 2010. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infectious Dis 201: 453-463.
16. Lindberg J, af Klint E, Ulfgren AK, Stark A, Andersson T, Nilsson P, Klareskog L, Lundeberg J, 2006. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther 8: R47.
17. 2007. KTH microarray core facility home page. Available at: http://www.ktharray.se/. Accessed October 2007.
18. 2007. R: A language and environment for statistical computing. Available at: http://www.cran.r-project.org/. Accessed October 2007.
19. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J, 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
20. Smyth GK, 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3. doi:10.2202/1544-6115.1027
21. Smyth GK, Speed T, 2003. Normalization of cDNA microarray data. Methods 31: 265-273.
22. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G, 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
23. Masocha W, Rottenberg ME, Kristensson K, 2006. Minocycline impedes African trypanosome invasion of the brain in a murine model. Antimicrob Agents Chemother 50: 1798-1804.
24. Livak, KJ, Schmittgen TD, 2001. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
25. Amin DN, Masocha W, Ngan'dwe K, Rottenberg M, Kristensson K, 2008. Suramin and minocycline treatment of experimental African trypanososmiasis at an early stage of parasite brain invasion. Acta Trop 106: 72-74.
26. Masocha W, Robertson B, Rottenberg ME, Mhlanga J, Sorokin L, Kristensson K, 2004. Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest 114: 689-694. (Pubitemid 39578759)
27. Mulenga C, Mhlanga JD, Kristensson K, Robertson B, 2001. Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic disease model. Neuropathol Appl Neurobiol 27: 77-85. (Pubitemid 32291190)
28. Thuita JK, Kagira JM, Mwangangi D, Matovu E, Turner CM, Masiga D, 2008. Trypanosoma brucei rhodesiense transmitted by a single Tsetse fly bite in Vervet Monkeys as a model of human African trypanosomiasis. PLOS Negl Trop Dis 2: e238. (Pubitemid 352002909)
29. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, Sorokin LM, 2006. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 203: 1007-1019.
30. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A, 2004. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432: 811-813. (Pubitemid 40037155)
31. Marques F, Rodrigues AJ, Sousa JC, Coppola G, Geschwind DH, Sousa N, Correia-Neves M, Palha JA, 2008. Lipocalin 2 is a choroid plexus acute-phase protein. J Cereb Blood Flow Metab 28: 450-455. (Pubitemid 351304271)
32. Lee S, Lee J, Kim S, Park JY, Lee WH, Mori K, Kim SH, Kim IK, Suk K, 2007. A dual role of lipocalin 2 in the apoptosis and deramification of activated microglia. J Immunol 179: 3231-3241.
33. Lee S, Park JY, Lee WH, Kim H, Park HC, Mori K, Suk K, 2009. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci 29: 234-249.
34. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM, 1997. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 99: 894-900. (Pubitemid 27123626)
35. Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, Barone FC, Feuerstein GZ, 2003. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. Mol Pharmacol 64: 833-840.